secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2022-03-17T23:59:59+00:00
Accession:  0001104659-22-034747
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx reports Q4/FY2021 results; Phase 2b enrollment ongoing for ibezapolstat
-----------------------------------------------------------------------------

- R&D expense FY2021: $2.0M (vs $2.2M in 2020); Q4 2021: $0.7M (vs $0.5M).
- G&A expense FY2021: $10.8M (vs $2.4M) due to stock-based compensation and professional fees.
- Phase 2a trial for C. difficile infection achieved 100% clinical cure and sustained cure with ibezapolstat.
- Phase 2b enrollment expected to complete in H2 2022, comparing ibezapolstat to vancomycin.
- New microbiome study with University of Houston comparing ibezapolstat to other CDI antibiotics anticipated H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465922034747/0001104659-22-034747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465922034747/tm229353d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-034747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer